UPDATE 3-AstraZeneca Q1 sales weak as generics take toll
*Q1 sales .29 bln vs consensus .44 bln * Q1 core EPS .23 vs consensus .10 * Tax gain and 1 mln patent settlement buoy earnings * Nudges up full-year EPS target range 5 cents to .95-7.25 * …
Read more on Reuters UK Focus via Yahoo! UK & Ireland Finance

Related posts:

1. Cosmetic Surgery Magazine Hires Top National Sales Director
2. Lastest Chin Surgery News
3. US Cosmetic Procedures and Products Industry
4. AP Interview: Treacy among royal wedding designers
5. Lastest Body Contouring News
6. New Houston Plastic Surgery Website Launched
7. New Trends in Breast Augmentation Met by Denver Plastic Surgeon
8. Lastest Chin Surgery News
9. Breast implants tests ‘encouraging’